Edition:
India

Dermira Inc (DERM.OQ)

DERM.OQ on NASDAQ Stock Exchange Global Select Market

26.53USD
11 Dec 2017
Change (% chg)

-- (--)
Prev Close
$26.53
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
129,158
52-wk High
$38.75
52-wk Low
$21.39

Select another date:

Tue, Nov 7 2017

BRIEF-Dermira posts Q3 loss $4.30/shr, says FDA accepts NDA for glycopyrronium tosylate

* Dermira reports third quarter 2017 financial results and announces that FDA accepts new drug application for glycopyrronium tosylate for the treatment of patients with primary axillary hyperhidrosis

BRIEF-Dermira and UCB agree to end collaboration agreement for Cimzia

* Dermira and UCB agree to end collaboration agreement for Cimzia

BRIEF-Dermira highlights new long-term safety data for glycopyrronium tosylate

* Dermira highlights new long-term safety data for glycopyrronium tosylate in primary axillary hyperhidrosis at fall clinical dermatology conference

BRIEF-Dermira completes patient enrollment in two phase 3 trials of olumacostat glasaretil for the treatment of acne vulgaris

* Dermira completes patient enrollment in two phase 3 pivotal trials of olumacostat glasaretil for the treatment of acne vulgaris

BRIEF-Dermira presents new data showing impact of primary axillary hyperhidrosis on patients

* Dermira -‍ presented new patient-reported outcomes data from two Phase 3 clinical trials showing impact of primary axillary hyperhidrosis on patients​

BRIEF-Dermira enters into agreement to license exclusive, worldwide rights to Lebrikizumab

* Dermira enters into agreement to license exclusive, worldwide rights to Lebrikizumab

BRIEF-UCB and Dermira announce US and EU regulatory submissions for Cimzia

* UCB AND DERMIRA ANNOUNCE U.S. AND EU REGULATORY SUBMISSIONS FOR CIMZIA (CERTOLIZUMAB PEGOL) FOR THE TREATMENT OF MODERATE-TO-SEVERE CHRONIC PLAQUE PSORIASIS Source text: http://bit.ly/2ty2bhV Further company coverage: (Gdynia Newsroom)

Select another date: